Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 149

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 149
---
 (Cont.)

| e. | Reconciliation of the theoretical tax expense to the actual tax expense: |

The main reconciling
item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of
deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred
taxes.

|                                                                            |     | Year ended   
 December 31, | 2023 |   |     |     |  2022 |   |
|:---------------------------------------------------------------------------|:----|:-------------|-----:|:--|:----|:----|------:|:--|
| Net loss, as reported in the consolidated statements of comprehensive loss |     |              |  683 |   |     |     | 1,213 |   |
| Statutory tax rate                                                         |     |              |   21 | % |     |     |    21 | % |
| Computed “expected” tax income                                             |     |              |  143 |   |     |     |   255 |   |
| Valuation allowance                                                        |     |              | (143 | ) |     |     |  (255 | ) |
| Taxes on income                                                            |     |              |    - |   |     |     |     - |   |

NOTE 5 – COMMITMENTS AND CONTINGENCIES

| a. | In 2023, the Company received an advance on account of shares of $1,200 (out of which $100 was received                                        
 in the beginning of 2024) remitted from qualified investors, which were initially deposited into an escrow account maintained by the Company’s 
 counsel. Upon certain events as described below which have since occurred as of November 2023, the investors would be entitled to receive      
 for their investment: (i) two (2) shares of the Company’s common stock and (ii) one common stock purchase warrant to purchase an               
 additional share of the Company’s Common Stock exercisable for a three year period, at a per share exercise price of $0.80. The                
 price per Unit was $0.80 (the “Earlier Private Placement”).                                                                                    |

Separately, between
April 2023 and September 2023, the Company received an advance on account of shares of $4,518.75 remitted from qualified investors. Upon
certain events as described below which have occurred as of November 2023, the investors would be entitled